<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469777</url>
  </required_header>
  <id_info>
    <org_study_id>0304649</org_study_id>
    <nct_id>NCT04469777</nct_id>
  </id_info>
  <brief_title>Erythropoietin in Patients With Recent Onset Indirect Traumatic Optic Neuropathy</brief_title>
  <official_title>A Comparative Study of the Effect of Intravenous Erythropoetin Versus Intravitreal Erythropoietin on Visual Function in Patients With Recent Onset Indirect Traumatic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect systemic erythropoietin versus intravitreal erythropoietin on visual function in
      patients having recent onset indirect traumatic optic neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the effect systemic erythropoietin versus
      intravitreal erythropoietin on visual function in patients having recent onset indirect
      traumatic optic neuropathy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are divided into two groups first group (10 patients) a trial of intravenous erythropoietin (20000 IU intravenous EPO injections for 3 days, patients that show no initial improvement after one month receive second dose) and second group (10 patients ) a trial of intravitreal injection of 2000 IU EPO in 0.2 ml of commercially available sterile EPREX 4000 solution, patients that show no initial improvement received second intravitreal injection a month later</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity using appropriate charts for assessment then convert into log of the minimum angle of resolution (logMAR) units to provide a numeric scale of visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flash visual-evoked potentials</measure>
    <time_frame>3 months</time_frame>
    <description>Flash VEP to detect amplitude reduction and latency in the optic nerve.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Traumatic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Intravitreal erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients with Intravitreal injection of 2000 IU EPO in 0.2 ml of commercially available sterile EPREX 4000 solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous erythropoietin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 patients with 20000 IU intravenous EPO injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>20000 IU intravenous EPO injections</description>
    <arm_group_label>Intravenous erythropoietin</arm_group_label>
    <arm_group_label>Intravitreal erythropoietin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as indirect traumatic optic neuropathy from severe blunt/
             penetrating trauma

        Exclusion Criteria:

          -  Patients with perforating ocular injuries were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai ElBahwash, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alexandria Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Mohamed Fahmy Doheim</investigator_full_name>
    <investigator_title>Prinicipal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

